CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
RAD001 (Everolimus)drug
Likely dose
RAD001 (Everolimus) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00449748
NCT00449748Phase 2Completed
CompareCT.gov

Evaluation of RAD001 as Therapy for Patients With Systemic Mastocytosis

M.D. Anderson Cancer Center·interventional·Posted Mar 21, 2007·Updated May 1, 2025

In Brief

A Phase 2 clinical trial evaluating RAD001 (Everolimus) for Systemic Mastocytosis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Mastocytosis
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2007
Enrollment StartApr 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.3 years ago

Interventions

RAD001 (Everolimus)drug

Oral RAD001 10 mg daily for 30 days